Advanced search
Publication Cover
International Journal of Hyperthermia Volume 40, 2023 - Issue 1
Submit an article Journal homepage
701
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Clinical efficacy of thermal ablation for the treatment of pulmonary carcinoid tumor: a propensity-matched analysis

Hao Yanga Department of Internal Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, ChinaView further author information
,
Mengqi Lib Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaCorrespondence[email protected]
View further author information
,
Tong Liuc Chongqing Bishan Hospital of Traditional Chinese Medicine, Chongqing, ChinaView further author information
&
Ling Luoa Department of Internal Medicine, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, ChinaCorrespondence[email protected]
View further author information
Article: 2225817 | Received 03 Apr 2023, Accepted 09 Jun 2023, Published online: 26 Jun 2023

Figures & data

Table 1. Baseline characteristics before and after propensity score matching, n (%).

Figure 1. Kaplan–Meier curves of PC. (A) thermal ablation versus non-ablation for OS after PSM; (B) thermal ablation versus non-ablation for LCSS after PSM. PC: pulmonary carcinoid; OS: overall survival; LCSS: lung cancer-specific survival; PSM: propensity score matching.

Figure 1. Kaplan–Meier curves of PC. (A) thermal ablation versus non-ablation for OS after PSM; (B) thermal ablation versus non-ablation for LCSS after PSM. PC: pulmonary carcinoid; OS: overall survival; LCSS: lung cancer-specific survival; PSM: propensity score matching.

Figure 2. Kaplan–Meier curves of PC. (A) thermal ablation versus non-ablation for OS of patients aged ≤70 years after PSM; (B) thermal ablation versus non-ablation for LCSS of patients aged ≤70 years after PSM; (C) thermal ablation versus non-ablation for OS of patients aged >70 years after PSM; (D) thermal ablation versus non-ablation for LCSS of patients aged >70 years after PSM. PC: pulmonary carcinoid; OS: overall survival; LCSS: lung cancer-specific survival; PSM: propensity score matching.

Figure 2. Kaplan–Meier curves of PC. (A) thermal ablation versus non-ablation for OS of patients aged ≤70 years after PSM; (B) thermal ablation versus non-ablation for LCSS of patients aged ≤70 years after PSM; (C) thermal ablation versus non-ablation for OS of patients aged >70 years after PSM; (D) thermal ablation versus non-ablation for LCSS of patients aged >70 years after PSM. PC: pulmonary carcinoid; OS: overall survival; LCSS: lung cancer-specific survival; PSM: propensity score matching.

Figure 3. Kaplan–Meier curves of PC. (A) thermal ablation versus non-ablation for OS of female patients after PSM; (B) thermal ablation versus non-ablation for LCSS of female patients after PSM; (C) thermal ablation versus non-ablation for OS of male patients after PSM; (D) thermal ablation versus non-ablation for LCSS of male patients after PSM. PC: pulmonary carcinoid; OS: overall survival; LCSS: lung cancer-specific survival; PSM: propensity score matching.

Figure 3. Kaplan–Meier curves of PC. (A) thermal ablation versus non-ablation for OS of female patients after PSM; (B) thermal ablation versus non-ablation for LCSS of female patients after PSM; (C) thermal ablation versus non-ablation for OS of male patients after PSM; (D) thermal ablation versus non-ablation for LCSS of male patients after PSM. PC: pulmonary carcinoid; OS: overall survival; LCSS: lung cancer-specific survival; PSM: propensity score matching.

Figure 4. Kaplan–Meier curves of PC. (A) thermal ablation versus non-ablation for OS of TC patients after PSM; (B) thermal ablation versus non-ablation for LCSS of TC patients after PSM; (C) thermal ablation versus non-ablation for OS of AC patients after PSM; (D) thermal ablation versus non-ablation for LCSS of AC patients after PSM. PC: pulmonary carcinoid; TC: Typical carcinoid; AC: atypical carcinoid; OS: overall survival; LCSS: lung cancer-specific survival; PSM: propensity score matching.

Figure 4. Kaplan–Meier curves of PC. (A) thermal ablation versus non-ablation for OS of TC patients after PSM; (B) thermal ablation versus non-ablation for LCSS of TC patients after PSM; (C) thermal ablation versus non-ablation for OS of AC patients after PSM; (D) thermal ablation versus non-ablation for LCSS of AC patients after PSM. PC: pulmonary carcinoid; TC: Typical carcinoid; AC: atypical carcinoid; OS: overall survival; LCSS: lung cancer-specific survival; PSM: propensity score matching.

Figure 5. Subgroup analysis for OS (A) and LCSS (B) in the matched population. OS: overall survival; LCSS: lung cancer-specific survival.

Figure 5. Subgroup analysis for OS (A) and LCSS (B) in the matched population. OS: overall survival; LCSS: lung cancer-specific survival.

Table 2. Univariable and multivariable analysis for overall survival in the whole cohort.

Table 3. Univariable and multivariable analysis for lung cancer-specific survival in the whole cohort.

Supplemental material

Supplemental Material

Download PDF (183.9 KB)

Data availability statement

All SEER data and information are publicly available at https://seer.cancer.gov/.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.